6533b86ffe1ef96bd12cd311

RESEARCH PRODUCT

A mid-term estimate of 2018/2019 vaccine effectiveness to prevent laboratory confirmed A(H1N1)pdm09 and A(H3N2) influenza cases in Sicily (Italy)

Vitale FrancescoClaudio CostantinoFabio TramutoGiuseppina Maria Elena ColombaEmanuele AmodioVincenzo Restivo

subject

Test-negative designAdultMaleVeterinary medicineSurveillance dataAdolescent030231 tropical medicinePopulationInfluenza seasonSurveillance networkSeasonal influenzaYoung Adult03 medical and health sciencesInfluenza A Virus H1N1 Subtype0302 clinical medicineInfluenza vaccine effectiveneInfluenza HumanHumansMedicine030212 general & internal medicineChildeducationSicilyVaccine PotencyAgededucation.field_of_studyGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryInfluenza A Virus H3N2 SubtypeInfluenza epidemicVaccinationPublic Health Environmental and Occupational HealthInfantvirus diseasesInfluenza aLaboratory confirmed caseMiddle AgedA h1n1 pdm09Infectious DiseasesInfluenza viruseInfluenza VaccinesCase-Control StudiesChild PreschoolMolecular MedicineFemaleImmunizationbusiness

description

Abstract Influenza season started in Italy during the month of October 2018, approaching the epidemic peak in January 2019. This report aim to explore the mid-term virologic surveillance data of the 2018–2019 influenza season in Sicily and to estimate the effectiveness of seasonal influenza vaccine (VE) against A(H1N1)pdm09 and A(H3N2) influenza viruses. A test-negative design was used to evaluate influenza VE. In Sicily, almost all influenza infections were sustained by influenza type A viruses, of which 62.3% were A(H3N2) and 36.3% A(H1N1)pdm09. A reduction of laboratory confirmed influenza cases in Sicilian population immunized against influenza were observed. In particular, an overall significant protective values were observed for any influenza A viruses (Adj-VE = 44.0%; 95%CI: 11.2–64.7%), especially among 15–64 years old age group (Adj-VE = 59.5%; 95%CI: 0.03–83.1) and among the elderly (Adj-VE = 73.6%; 95% CI: 29.4–90.2).

yearjournalcountryeditionlanguage
2019-02-26Vaccine
https://doi.org/10.1016/j.vaccine.2019.08.014